S&P 500   3,110.17 (+0.21%)
DOW   27,873.68 (+0.39%)
QQQ   201.82 (+0.06%)
T   37.74 (+0.37%)
F   8.88 (+1.95%)
DIS   148.16 (+0.86%)
S&P 500   3,110.17 (+0.21%)
DOW   27,873.68 (+0.39%)
QQQ   201.82 (+0.06%)
T   37.74 (+0.37%)
F   8.88 (+1.95%)
DIS   148.16 (+0.86%)
S&P 500   3,110.17 (+0.21%)
DOW   27,873.68 (+0.39%)
QQQ   201.82 (+0.06%)
T   37.74 (+0.37%)
F   8.88 (+1.95%)
DIS   148.16 (+0.86%)
S&P 500   3,110.17 (+0.21%)
DOW   27,873.68 (+0.39%)
QQQ   201.82 (+0.06%)
T   37.74 (+0.37%)
F   8.88 (+1.95%)
DIS   148.16 (+0.86%)
Log in

GlaxoSmithKline Stock Price, Forecast & Analysis (NYSE:GSK)

$44.02
-0.02 (-0.05 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$43.95
Now: $44.02
$44.20
50-Day Range
$41.11
MA: $43.48
$45.71
52-Week Range
$36.41
Now: $44.02
$46.01
Volume1.91 million shs
Average Volume2.88 million shs
Market Capitalization$109.78 billion
P/E Ratio13.93
Dividend Yield4.33%
Beta0.7
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$41.14 billion
Cash Flow$4.11 per share
Book Value$8.93 per share

Profitability

Net Income$4.84 billion

Miscellaneous

Employees95,490
Outstanding Shares2,494,210,000
Market Cap$109.78 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Friday, May 3rd. Shareholders of record on Friday, May 17th will be paid a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.50%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its earnings results on Wednesday, October, 30th. The pharmaceutical company reported $0.95 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.85 by $0.10. The pharmaceutical company had revenue of $11.57 billion for the quarter, compared to analysts' expectations of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

19 brokers have issued 1-year target prices for GlaxoSmithKline's shares. Their forecasts range from $36.95 to $50.00. On average, they expect GlaxoSmithKline's stock price to reach $42.99 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for GlaxoSmithKline.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 7,550,000 shares, an increase of 17.4% from the September 30th total of 6,430,000 shares. Based on an average trading volume of 2,430,000 shares, the days-to-cover ratio is currently 3.1 days. Currently, 0.3% of the shares of the company are sold short. View GlaxoSmithKline's Current Options Chain.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), Bank of America (BAC), General Electric (GE), Johnson & Johnson (JNJ), AbbVie (ABBV), Intel (INTC) and Exxon Mobil (xom).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.61%), Kahn Brothers Group Inc. DE (0.06%), Kahn Brothers Group Inc. DE (0.06%), Envestnet Asset Management Inc. (0.04%), Kornitzer Capital Management Inc. KS (0.04%) and First Trust Advisors LP (0.04%). View Institutional Ownership Trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Letko Brosseau & Associates Inc., Crossmark Global Holdings Inc., Janney Capital Management LLC, Anchor Capital Advisors LLC, CIBC Asset Management Inc, Iowa State Bank and Diamond Hill Capital Management Inc.. View Insider Buying and Selling for GlaxoSmithKline.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Beutel Goodman & Co Ltd., Douglas Lane & Associates LLC, First Trust Advisors LP, Segantii Capital Management Ltd, Bfsg LLC, Envestnet Asset Management Inc. and Cohen Klingenstein LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $44.06.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $109.89 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com/.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  653 (Vote Outperform)
Underperform Votes:  1,009 (Vote Underperform)
Total Votes:  1,662
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel